Author:
Hulstaert F.,Blennow K.,Ivanoiu A.,Schoonderwaldt H.C.,Riemenschneider M.,Deyn P.P. De,Bancher C.,Cras P.,Wiltfang J.,Mehta P.D.,Iqbal K.,Pottel H.,Vanmechelen E.,Vanderstichele H.
Abstract
Objective: To evaluate CSF levels of β-amyloid(1-42) (Aβ42) alone and in combination with CSF tau for distinguishing AD from other conditions.Methods: At 10 centers in Europe and the United States, 150 CSF samples from AD patients were analyzed and compared with 100 CSF samples from healthy volunteers or patients with disorders not associated with pathologic conditions of the brain (CON), 84 patients with other neurologic disorders (ND), and 79 patients with non-Alzheimer types of dementia (NAD). Sandwich ELISA techniques were used on site for measuring Aβ42 and tau.Results: Median levels of Aβ42 in CSF were significantly lower in AD (487 pg/mL) than in CON (849 pg/mL; p = 0.001), ND (643 pg/mL; p = 0.001), and NAD (603 pg/mL; p = 0.001). Discrimination of AD from CON and ND was significantly improved by the combined assessment of Aβ42 and tau. At 85% sensitivity, specificity of the combined test was 86% (95%CI: 81% to 91%) compared with 55% (95%CI: 47% to 62%) for Aβ42 alone and 65% (95%CI: 58% to 72%) for tau. The combined test at 85% sensitivity was 58% (95%CI: 47% to 69%) specific for NAD. The APOE e4 gene load was negatively correlated with Aβ42 levels not only in AD but also in NAD.Conclusions: The combined measure of CSF Aβ42 and tau meets the requirements for clinical use in discriminating AD from normal aging and specific neurologic disorders.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference31 articles.
1. Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI). 22The Reagan Institute Working Groups are planned and organized by Z. S. Khachaturian and T.S. Radebaugh; Fax: 301-879-2023; E-mail: zaven@idt.net.
2. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer’s disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 1999 (in press).
3. Vanderstichele H, Blennow K, D’Heuvaert N, et al. Development of a specific diagnostic test for measurement of β-amyloid(1-42) [βA4(1-42)] in CSF. In: Fisher A, Hanin I, Yoshida M, eds. Progress in Alzheimer’s and Parkinson’s diseases. New York:Plenum Press, 1998: 773–778.
4. Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme-Linked Immunosorbent Assay
5. Van de Voorde A, Vanmechelen E, Vandermeeren M, Dessaint F, Beeckman W, Cras P. Detection of tau in cerebrospinal fluid. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer’s disease and related disorders. Chichester:John Wiley & Sons Ltd., 1995: 189–195.
Cited by
638 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献